Nomura Asset Management Co. Ltd. Buys 1,665 Shares of IDEXX Laboratories, Inc. $IDXX

Nomura Asset Management Co. Ltd. lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,561 shares of the company’s stock after buying an additional 1,665 shares during the period. Nomura Asset Management Co. Ltd. owned about 0.08% of IDEXX Laboratories worth $32,481,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of IDXX. Vanguard Group Inc. grew its stake in shares of IDEXX Laboratories by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock worth $4,139,001,000 after acquiring an additional 146,427 shares in the last quarter. Geode Capital Management LLC boosted its holdings in IDEXX Laboratories by 2.3% during the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after purchasing an additional 54,402 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after purchasing an additional 825,965 shares during the last quarter. Bank of New York Mellon Corp grew its position in IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares in the last quarter. Finally, Invesco Ltd. increased its stake in IDEXX Laboratories by 0.5% in the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock valued at $489,832,000 after buying an additional 5,418 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on IDXX shares. Morgan Stanley boosted their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. UBS Group lifted their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $730.50.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares of the company’s stock, valued at $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $670.21 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $735.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The stock’s fifty day moving average price is $652.36 and its two-hundred day moving average price is $592.66. The firm has a market cap of $53.52 billion, a PE ratio of 55.80, a PEG ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the company earned $2.80 EPS. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.